4:16 PM ET
8-K
Capital Raise
Fate Therapeutics Capital Raise
Fate Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program for up to $100 million of its common stock. The company is not obligated to sell any shares and will pay a commission of up to 3.0% on any gross proceeds. This program replaces a previous ATM facility that was terminated concurrently.
- Counterparty
- Leerink Partners LLC